News
NXEN
0.0001
NaN%
--
Weekly Report: what happened at NXEN last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at NXEN last week (0525-0529)?
Weekly Report · 06/01 09:20
Weekly Report: what happened at NXEN last week (0518-0522)?
Weekly Report · 05/25 09:20
Weekly Report: what happened at NXEN last week (0511-0515)?
Weekly Report · 05/18 09:20
Weekly Report: what happened at NXEN last week (0504-0508)?
Weekly Report · 05/11 09:20
Weekly Report: what happened at NXEN last week (0427-0501)?
Weekly Report · 05/04 09:19
Weekly Report: what happened at NXEN last week (0420-0424)?
Weekly Report · 04/27 09:20
Weekly Report: what happened at NXEN last week (0413-0417)?
Weekly Report · 04/20 09:18
Weekly Report: what happened at NXEN last week (0406-0410)?
Weekly Report · 04/13 09:20
Weekly Report: what happened at NXEN last week (0330-0403)?
Weekly Report · 04/06 09:20
Weekly Report: what happened at NXEN last week (0323-0327)?
Weekly Report · 03/30 09:20
Weekly Report: what happened at NXEN last week (0316-0320)?
Weekly Report · 03/23 09:19
Weekly Report: what happened at NXEN last week (0309-0313)?
Weekly Report · 03/16 09:18
Weekly Report: what happened at NXEN last week (0302-0306)?
Weekly Report · 03/09 09:19
Weekly Report: what happened at NXEN last week (0223-0227)?
Weekly Report · 03/02 09:19
Weekly Report: what happened at NXEN last week (0216-0220)?
Weekly Report · 02/23 09:19
Weekly Report: what happened at NXEN last week (0209-0213)?
Weekly Report · 02/16 09:19
Weekly Report: what happened at NXEN last week (0202-0206)?
Weekly Report · 02/09 09:19
Weekly Report: what happened at NXEN last week (0126-0130)?
Weekly Report · 02/02 09:19
Weekly Report: what happened at NXEN last week (0119-0123)?
Weekly Report · 01/26 09:19
More
Webull provides a variety of real-time NXEN stock news. You can receive the latest news about Nexien Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About NXEN
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. The Company is utilizing cannabinoids as the active pharmaceutical ingredients to develop synthetic pharmaceuticals in strict accordance with the U.S. FDA pre-clinical and clinical pathways. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.